KR20180043810A - Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물 - Google Patents

Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물 Download PDF

Info

Publication number
KR20180043810A
KR20180043810A KR1020187008146A KR20187008146A KR20180043810A KR 20180043810 A KR20180043810 A KR 20180043810A KR 1020187008146 A KR1020187008146 A KR 1020187008146A KR 20187008146 A KR20187008146 A KR 20187008146A KR 20180043810 A KR20180043810 A KR 20180043810A
Authority
KR
South Korea
Prior art keywords
mmol
ring
mixture
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187008146A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 마크 웬글로스키
나타샤 브르즈만스
챈드라세카 브이. 미두투루
네일 비풀코
Original Assignee
블루프린트 메디신즈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블루프린트 메디신즈 코포레이션 filed Critical 블루프린트 메디신즈 코포레이션
Publication of KR20180043810A publication Critical patent/KR20180043810A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187008146A 2015-08-26 2016-08-25 Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물 Withdrawn KR20180043810A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (1)

Publication Number Publication Date
KR20180043810A true KR20180043810A (ko) 2018-04-30

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187008146A Withdrawn KR20180043810A (ko) 2015-08-26 2016-08-25 Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물

Country Status (17)

Country Link
US (2) US10017512B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341374A1 (cg-RX-API-DMAC7.html)
JP (1) JP6877407B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180043810A (cg-RX-API-DMAC7.html)
CN (1) CN108137607B (cg-RX-API-DMAC7.html)
AR (1) AR105836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016311426B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003588A2 (cg-RX-API-DMAC7.html)
CA (1) CA2995997A1 (cg-RX-API-DMAC7.html)
HK (1) HK1255330A1 (cg-RX-API-DMAC7.html)
IL (1) IL257702A (cg-RX-API-DMAC7.html)
MX (1) MX2018002407A (cg-RX-API-DMAC7.html)
PH (1) PH12018500397A1 (cg-RX-API-DMAC7.html)
RU (1) RU2744974C2 (cg-RX-API-DMAC7.html)
TW (1) TW201713665A (cg-RX-API-DMAC7.html)
WO (1) WO2017035354A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801881B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN111936138B (zh) * 2018-02-05 2024-03-08 深圳市原力生命科学有限公司 作为ep4受体拮抗剂的杂二环化合物
JP2021519297A (ja) * 2018-03-28 2021-08-10 フォチョン・ファーマシューティカルズ・リミテッドFochon Pharmaceuticals, Ltd. Trkキナーゼ阻害剤としての大環状化合物
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
ES3013815T3 (en) * 2019-02-27 2025-04-15 Ferro Therapeutics Inc Compounds with ferroptosis inducing activity and methods of their use
HUE064283T2 (hu) 2019-04-12 2024-02-28 Blueprint Medicines Corp Az (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il) piperazinil)-pirimidin-5-il)etán-1-amin kristályos formái és elõállítási eljárásai
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266519C (en) * 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
MXPA06011423A (es) * 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2010352577A1 (en) * 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US20150218652A1 (en) * 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9556181B2 (en) * 2013-02-01 2017-01-31 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE067779T2 (hu) 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3259264B1 (en) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
HK1255330A1 (zh) 2019-08-16
US20170066773A1 (en) 2017-03-09
CN108137607B (zh) 2021-04-06
WO2017035354A1 (en) 2017-03-02
US20190169194A1 (en) 2019-06-06
PH12018500397A1 (en) 2018-08-29
AR105836A1 (es) 2017-11-15
BR112018003588A2 (pt) 2018-09-25
AU2016311426A1 (en) 2018-04-05
IL257702A (en) 2018-04-30
CN108137607A (zh) 2018-06-08
TW201713665A (zh) 2017-04-16
RU2744974C2 (ru) 2021-03-17
ZA201801881B (en) 2019-05-29
AU2016311426B2 (en) 2021-05-20
CA2995997A1 (en) 2017-03-02
EP3341374A1 (en) 2018-07-04
RU2018110379A3 (cg-RX-API-DMAC7.html) 2019-12-26
JP6877407B2 (ja) 2021-05-26
RU2018110379A (ru) 2019-09-27
JP2018528200A (ja) 2018-09-27
MX2018002407A (es) 2018-11-29
US10017512B2 (en) 2018-07-10
US11046697B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
RU2744974C2 (ru) Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
US12595265B2 (en) Inhibitors of activin receptor-like kinase
JP6494624B2 (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
TWI733713B (zh) 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物
JP2022525749A (ja) Jakキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
EP3632903B1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
AU2019326368A1 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
JP2023522863A (ja) Egfr阻害剤としての三環式化合物
JP2023522725A (ja) 3-アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
TW202317560A (zh) Cdk2抑制劑及其使用方法
EP3434674B1 (en) ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer
JP2025519624A (ja) Hpk1阻害剤およびその医薬における使用
TW202542120A (zh) 化合物及其用途
EA040675B1 (ru) Ингибиторы активин-подобной рецепторной киназы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid